GetTopicDetailResponse(id=597725653fd, topicName=伊匹單抗, introduction=伊匹單抗, content=null, image=null, comments=2, allHits=2431, url=https://h5.medsci.cn/topic?id=25653, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=11709, tagList=[TagDto(tagId=11709, tagName=伊匹單抗)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2252954, encodeId=41e022529542e, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a> <a href='/topic/show?id=597725653fd' target=_blank style='color:#2F92EE;'>#伊匹單抗#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#納武利尤單抗#</a>, objectTitle=Lancet Oncol：黑色素瘤腦轉(zhuǎn)移患者使用伊匹單抗聯(lián)合納武利尤單抗與單獨使用納武利尤單抗的7年隨訪結(jié)果, objectType=article, longId=863980, objectId=42ff86398040, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250207/1738890993044_8538692.jpg, objectUrl=/article/show_article.do?id=42ff86398040, replyNumber=0, likeNumber=52, createdTime=2025-02-21, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=42ff86398040, moduleTitle=Lancet Oncol：黑色素瘤腦轉(zhuǎn)移患者使用伊匹單抗聯(lián)合納武利尤單抗與單獨使用納武利尤單抗的7年隨訪結(jié)果, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=42ff86398040)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2178612, encodeId=e5bd21e86125b, content=<a href='/topic/show?id=597725653fd' target=_blank style='color:#2F92EE;'>#伊匹單抗#</a> <a href='/topic/show?id=d1559341310' target=_blank style='color:#2F92EE;'>#轉(zhuǎn)移性尿路上皮癌#</a> <a href='/topic/show?id=fc2be734870' target=_blank style='color:#2F92EE;'>#納武利尤單抗#</a>, objectTitle=讀書報告 | TITAN-TCC研究：含鉑化療后進展的尿路上皮癌患者接受定制的納武利尤單抗聯(lián)合伊匹木單抗免疫治療的II期臨床試驗, objectType=article, longId=807722, objectId=92ce80e72221, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=92ce80e72221, replyNumber=0, likeNumber=164, createdTime=2024-01-01, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=92ce80e72221, moduleTitle=讀書報告 | TITAN-TCC研究：含鉑化療后進展的尿路上皮癌患者接受定制的納武利尤單抗聯(lián)合伊匹木單抗免疫治療的II期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=92ce80e72221)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2111059, encodeId=50f6211105922, content=瘤內(nèi)<a href='/topic/show?id=d17466492d5' target=_blank style='color:#2F92EE;'>#溶瘤病毒#</a>V937加<a href='/topic/show?id=597725653fd' target=_blank style='color:#2F92EE;'>#伊匹單抗#</a>治療 晚期<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a>的療效，仍然從黑色素瘤入手，這是明智的。, objectTitle=J Immunother Cancer：瘤內(nèi)溶瘤病毒V937加伊匹木單抗治療 晚期黑色素瘤的療效, objectType=article, longId=756232, objectId=f243e56232e8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221121/1669073265617_4754896.webp, objectUrl=/article/show_article.do?id=f243e56232e8, replyNumber=0, likeNumber=307, createdTime=2023-01-21, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f243e56232e8, moduleTitle=J Immunother Cancer：瘤內(nèi)溶瘤病毒V937加伊匹木單抗治療 晚期黑色素瘤的療效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f243e56232e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=887715, encodeId=953d88e71578, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a><a href='/topic/show?id=597725653fd' target=_blank style='color:#2F92EE;'>#伊匹單抗#</a><a href='/topic/show?id=4e9ae7349f2' target=_blank style='color:#2F92EE;'>#納武單抗#</a>聯(lián)合可能更好, objectTitle=Lancet oncol：納武單抗 vs 伊匹單抗作為高危黑色素瘤術(shù)后輔助治療的4年隨訪結(jié)果！, objectType=article, longId=201125, objectId=c5a52011256e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020923/1600850266428_2110107.PNG, objectUrl=/article/show_article.do?id=c5a52011256e, replyNumber=0, likeNumber=299, createdTime=2020-09-23, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5a52011256e, moduleTitle=Lancet oncol：納武單抗 vs 伊匹單抗作為高危黑色素瘤術(shù)后輔助治療的4年隨訪結(jié)果！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c5a52011256e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
